Xeris Wins FDA Approval of Recorlev for Cushing’s Syndrome

The FDA has approved Xeris Biopharma’s Recorlev (levoketoconazole) for treating hypercortisolemia in adults with Cushing’s syndrome who are unable to undergo surgery.
Source: Drug Industry Daily